Aerami Therapeutics To Merge In SPAC Deal With FoxWayne Enterprises Acquisition Corp. In ~$250M Deal
New entity poised to accelerate the development of Aerami's diverse pipeline of next-generation inhaled therapies
AER-901, Aerami's proprietary inhaled, nebulized formulation of imatinib, targeted to advance in